Company profile
OmniAb, Inc.
NASDAQ: OABI · Healthcare · Biotechnology
#558 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
50DFH 59DQ 46GM 33SS 50
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ listing tenure, 3-yr revenue growth
Methodology →Revenue TTM
$28.9M
Rev growth YoY (TTM)
+8.1%
Net income (FY)
-$64.8M
Employees
89
as of 2026-08-13
Market cap
$495.8M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$18.7M$18.7M2025
Net income-$64.8M-$64.8M2025
Operating income-$69.0M-$69.0M2025
Total assets$300.9M$300.9M2025
Liabilities$33.9M$33.9M2025
Equity$267.0M$267.0M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Service89%
Royalty11%
By geography
Not disclosed.
The read
What is OmniAb, Inc.’s revenue?
OmniAb, Inc. booked $18.7M in FY2025 revenue, contracting 29% year over year — slower than 76% of Healthcare companies we track, at a -347.0% net margin.
Peers · Healthcare
Ethema Health Corporation57CAurora Spine Corporation65BRennova Health, Inc.——Fuse Medical, Inc.——PD-Rx Pharmaceuticals, Inc.70BAvicanna Inc.55CNeighbors
Alameda →Key facts
CEOMatthew W. Foehr
SectorHealthcare
IndustryBiotechnology
HeadquartersEmeryVille, CA
ExchangeNASDAQ: OABI
Employees89
IPO date2021-09-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.